We help leading pharmaceutical and biotech companies navigate and resolve contentious issues arising out of their life sciences contracts, especially those involving highly technical, IP-rich subject matter.

Our team has in-depth knowledge of the drug development life cycle from bench-scale production through to trial phases, regulatory approval, manufacture scale-up and commercialisation. This informed expertise means we are able to resolve a wide spectrum of disputes such as those relating to licensing IP and know-how, technical/quality agreements, research collaboration contracts, API manufacturing, development services, supply and distribution.

We also advise on product liability and misuse of confidential information matters related to medicinal drugs and medical devices.

Our clients trust us to assess and manage complex disputes through to resolution on a spread of issues including breach of contract, wrongful termination, royalty rate assessments, trial phases, GMP and regulatory compliance, product liability and misuse of confidential information. Where needed, we bring in expertise from our specialist life sciences regulatory, patent litigation and commercial contracts teams.

If unavoidable, we vigorously deploy our strong experience in litigation, arbitration and other forms of ADR such as mediation, expert determination and judicial review to protect our clients’ interests and enforce their rights.

Key contact

Mark Brown

Contact

Experience

Licence fees and royalty rate dispute of a pharma product: Representing a pharma company in relation to a claim for royalties under a collaboration agreement for the development of a monoclonal antibody blockbuster drug.

Wrongful termination and breaches of pharma product manufacture and supply contracts: Representing a pharma company in relation to the contested termination of manufacture and supply contracts of a licensed active pharmaceutical ingredient.

Breaches of technical quality contracts and regulatory compliance: Representing a pharma company in relation to claims against CMO for breaches of technical quality agreement, GMP guidelines and CAPAs concerning OOS API batches.

Breach of reasonable endeavours obligations under licence agreement: Advising a pharma company in a claim relating to breaches of a licence, development and commercialisation agreement for failure to comply with “reasonable endeavours” obligations to promote and sell a peptide drug.

Master Services Agreement for human drug trials: Advising a biotech client in relation to breaches of work orders under a master services agreement for the conduct of clinical trials.

Misuse of confidential information: Representing a pharma company in relation to allegations of misuse of confidential information relating to the formula of an active pharmaceutical ingredient.

Latest articles

What others say

“Bristows are a class act through and through, a quality firm providing in-depth coverage.”

Chambers and Partners 2022

“We like to be able to take them into complex situations where they can be practical, and we like that they’re adaptable.”

Chambers and Partners 2022

“Their sector experience is really broad and deep.”

Chambers and Partners 2022

“They are bright, practical and creative lawyers, who really understand the industry, in particular on the data protection side.”

Legal 500 2022

“The team are collaborative and a real pleasure to work with.”

Legal 500 2022

“No other firm in media/reputation management/data protection has such strength in depth.”

Legal 500 2022

“The team has a unique offering in the media law field.”

Legal 500 2022

“They are specialists in defamation/privacy and data protection and also heavyweights in Intellectual Property. This is an especially attractive offer to clients in the internet age when claims arising from acts online can encompass several diverse causes of action.”

Legal 500 2022

“Strong scientific/technical knowledge base and experience.”

Legal 500 2022

“A stellar team of exceptionally strong lawyers.”

Legal 500 2022

“All very approachable, give quick and to the point advice.”

Legal 500 2022

“A strong team in relation to IT disputes generally, particularly those with an IP element and video games. Pragmatic and commercial.”

Legal 500 2022

“[The regulatory team] are committed to not only giving high quality advice but also supporting education and upskilling within the client team to support continuous learning and improvement.”

Legal 500 2022

“Partners are very hands-on, always available and a pleasure to work with.”

Legal 500 2022

“The quality that Bristows provides is exceptionally high.”

Legal 500 2022

Recent rankings and awards

Life Sciences - Band 1
Chambers and Partners UK 2021

Life Sciences: Transactional - Band 2
Chambers and Partners UK 2021

Life Sciences and Healthcare - Tier 1
Legal 500 2021

Commercial Litigation
Leaders League UK 2020